Data from: Integrated metabolomics and metagenomics analysis of plasma and urine identified microbial metabolites associated with coronary heart disease

Coronary heart disease (CHD) is top risk factor for health in modern
society, causing high mortality rate each year. However, there is no
reliable way for early diagnosis and prevention of CHD so far. So study
the mechanism of CHD and development of novel biomarkers is urgently
needed. In this study, metabolomics and metagenomics technology are
applied to discover new biomarkers from plasma and urine of 59 CHD
patients and 43 healthy controls and trace their origin. We identify
GlcNAc-6-P which has good diagnostic capability and can be used as
potential biomarkers for CHD, together with mannitol and 15 plasma
cholines. These identified metabolites show significant correlations with
clinical biochemical indexes. Meanwhile, GlcNAc-6-P and mannitol are
potential metabolites originated from intestinal microbiota. Association
analysis on species and function levels between intestinal microbes and
metabolites suggest a close correlation between Clostridium sp. HGF2 and
GlcNAc-6-P, Clostridium sp. HGF2, Streptococcus sp. M143, Streptococcus
sp. M334 and mannitol. These suggest the metabolic abnormality is
significant and gut microbiota dysbiosis happens in CHD patients.